


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by formula (I)



wherein R¹ and R² each independently represents a hydrogen atom, C1-8 alkyl, a halogen atom, C1-4 alkoxy, nitro, trihalomethyl, trihalomethoxy, trihalomethylthio, cyano, C1-4 alkylthio or NR⁷R⁸, in which R⁷ and R⁸ each independently represents a hydrogen atom or C1-4 alkyl;

R³ represents C1-8 alkyl which may be substituted with a 1-3 halogen atom(s) or phenyl;

R⁴ represents a hydrogen atom or C1-8 alkyl;

R⁵ and R⁶ each independently represents a hydrogen atom or C1-4 alkyl, or R⁵ and R⁶ may be together with their neighboring carbon atom to form a carbocyclic ring;

X represents a sulfur atom, an oxygen atom or a nitrogen atom which may have a substituent(s);

ringA represents a cyclic group which may have a substituent(s);

4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 3,4-dihydro-1H-isoquinolin-2-yl,

or a salt thereof, or a solvate thereof or a prodrug thereof.

2. (currently amended): The compound according to claim 1, wherein the ~~eye~~lie group represented by ring A is 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 4-phenylpiperidin-1-yl, 4-phenylpiperazin-1-yl, 1,3-dihydro-2H-isoindole-2-yl, 4-(4-chlorophenyl)piperazin-1-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

3. (currently amended): The compound according to claim 2 1, wherein the ~~eye~~lie group represented by ring A is 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

4. (currently amended): The compound according to claim 1, wherein the compound is

(1) [3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,

(2) ~~———— [3-(2-{5-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,~~

(3)(2) [3-(2-{5-ethyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,

(4) ~~———— [3-(2-{5-isopropyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,~~

(5)(3) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,

(6) ~~———— [3-(2-{5-ethyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,~~

(7)(4) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,

- (8)(5) [2-fluoro-3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,
- (9) ~~———— (2-fluoro-3-{2-[5-methyl-2-(4-phenylpiperidin-1-yl)-1,3-thiazol-4-yl]ethoxy}phenyl)acetic acid,~~
- (10) ~~———— (3-{2-[5-methyl-2-(4-phenylpiperazin-1-yl)-1,3-thiazol-4-yl]ethoxy}phenyl)acetic acid,~~
- (11) ~~———— (3-{2-[2-(1,3-dihydro-2H-isoindole-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-2-fluorophenyl)acetic acid,~~
- (12) ~~———— [3-(2-{2-[4-(4-chlorophenyl)piperazin-1-yl]-5-methyl-1,3-thiazol-4-yl}ethoxy)-2-fluorophenyl]acetic acid or~~
- (13)(6) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid.

5. (currently Amended): A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, or a salt thereof, ~~or a solvent thereof or a prodrug thereof~~, and a pharmaceutically acceptable carrier.

6. (currently amended): The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a ~~preventive and/or therapeutic agent for a PPAR-mediated disease~~ hyperlipidemia or adiposity.

7-8 (canceled).

9. (currently amended): A ~~medicament~~ pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, or a salt thereof, ~~or a solvent~~

thereof or a prodrug thereof and one kind or more kinds components selected from the group consisting of a MTP inhibitor, a HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a fibrate drug, an ACAT inhibitor, a 5-lipoxygenase inhibitor, a cholesterol absorption inhibitor, a bile acid absorption inhibitor, a Na⁺/bile acid transporter inhibitor, LDL receptor activator, LDL receptor expression enhancer, a pancreatic lipase inhibitor, a probucol formulation, a nicotine acid formulation and a cholesterol ester transporter protein inhibitor.

10. (currently amended): A method for ~~prevention and/or treatment for~~ PPAR-mediated disease hyperlipidemia or adiposity in a mammal, which comprises administering to a mammal an effective amount of a compound ~~represented by formula (I) according to claim 1,~~ selected from the group consisting of

(1) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,

(2) [2-fluoro-3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid, and

(3) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid

or a salt thereof, or a solvent thereof or a prodrug thereof.

11. (Canceled)

12. (new): A compound selected from a group consisting of

(1) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid and

(2) [2-fluoro-3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid.

13. (new): A compound of (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid.